register free | resend password


TissueGen Featured in Nature.com Webcast on Innovations in Drug Delivery Technology

TissueGen's ELUTE Fiber Provides Controlled Sustained Delivery of Sensitive Drugs Enabling Nerve Regeneration and Tissue Engineering

ID: 1494156
recent pressrelease next pressrelease

(businesspress24) - DALLAS, TX -- (Marketwired) -- 03/22/17 -- , developer of , a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering, today announced that its founder and CSO, Dr. Kevin Nelson, will participate in a BioPharma Dealmakers webcast featuring five companies'' innovative drug delivery technologies. The webcast, part of the BioPharma Dealmakers series, is scheduled for 11:00 am EDT on March 29th. Register .

This webcast will highlight how innovative new approaches to biologic and pharmaceutical delivery may enable breakthroughs in oncology, treatment of CNS diseases and women''s health. Presented technologies will include fiber-based drug delivery for implantable and topical devices, digitally controlled needle-free devices, sustained and controlled transdermal delivery technology, targeted penetration matrix technology for non-invasive delivery and location-specific nano machines for chemotherapy payload delivery.

TissueGen''s ELUTE fiber may directly replace standard fibers used in medical devices currently on the market and may enable significantly improved clinical outcomes by delivering sensitive therapeutic agents in controlled, sustained release profiles. Dr. Nelson founded TissueGen in 2000 following his work as a faculty member at University of Texas at Arlington, while simultaneously pursuing development of a fiber-based, biodegradable vascular stent to deliver gene therapy to the vessel wall, as well as drug-loaded microspheres for improved wound healing.

Other webcast participants include:

, Chief Executive Officer of Portal Instruments Inc.

, Chief Business Officer of Corium International

, Chief Scientific Officer of Phosphagenics Limited

, Chief Scientific Officer of TrioxNano

, Editor of BioPharma Dealmakers.

are dedicated to small and large companies looking for commercial partnerships. Read the quarterly in Nature Biotechnology and Nature Reviews Drug Discovery. Register .

TissueGen® Inc. is the developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering. TissueGen manufactures biodegradable polymer-based fibers with the broadest drug delivery capabilities available today. ELUTE fiber can directly replace standard fibers used in medical devices currently on the market and may enable significantly improved clinical outcomes by delivering sensitive therapeutic agents directly at the topical or implant site in controlled, sustained release profiles. With localized delivery of pharmaceuticals and biologics, ELUTE fiber may enable medical device developers to guide the body''s healing and regenerative processes. For more information, please visit .

Jordan Bouclin


SVM Public Relations
401-490-9700



More information:
https://www.aquabarandgrill.co.uk/section/4/1/restaurant-croydon http://www.coloreart.com https://shealywellness.com/ http://www2.marketwire.com/mw/frame_mw?attachid=3121638 http://www.parksassociates.com/events/connections-us http://www.tissuegen.com



Keywords (optional):

drug-delivery-technology, drug-delivery, nerve-regeneration, tissue-engineering, biodegradable-fiber,



Company information / Profile:

PressRelease by

Requests:



PressContact / Agency:



published by: Marketwired
print pressrelease  send to a friend  

Date: 03/22/2017 - 14:00
Language: English
News-ID 1494156
Character count: 3587
Kontakt-Informationen:
Firma: TissueGen, Inc.
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: DALLAS, TX
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 251

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 409
Register today: 0
Register yesterday: 1
Members online: 0
Guests online: 48


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.